A. Tzouvelekis (Athens, Greece)
This session is built from abstracts published on the ERS Congress platform from 23 August, in an e-poster pdf format with a 3-minute audio narration. Participants and chairs of the session are invited to access all e-posters from 23 August to 4 September prior to the 1-hour live, online discussion scheduled from September 5-7. Please note that during live discussion there will be NO e-poster/abstract presentations, only discussion.
Blood Krebs von den Lungen-6 predicts mortality in patients with acute exacerbation of interstitial lung disease
M. Choi (Seoul, Republic of Korea), J. Yoon (Seoul, Republic of Korea), S. Choi (Seoul, Republic of Korea), J. Song (Seoul, Republic of Korea)
|   |
Serum concentrations of KL-6 in patients with IPF and lung cancer and serial measurements of KL-6 in IPF patients treated with antifibrotic therapy
. d'Alessandro (Siena, Italy), L. Bergantini (Siena, Italy), P. Cameli (Siena, Italy), M. Pieroni (Siena, Italy), R. Refini (Siena, Italy), P. Sestini (Siena, Italy), E. Bargagli (Siena, Italy)
| |
Identifying serum molecular biomarkers that distinguish emphysema and early fibrotic interstitial lung disease.
C. Ihuoma (Edinburgh, United Kingdom), A. Przybylski (Edinburgh, United Kingdom), C. Boz (Edinburgh, United Kingdom), F. Li (Edinburgh, United Kingdom), E. Van Beek (Edinburgh, United Kingdom), N. Hirani (Edinburgh, United Kingdom)
| |
Differential expression of PD-1/PD-L1 axis and CD4/CD8 ratio in mediastinal lymph nodes of patients with idiopathic pulmonary fibrosis and lung cancer
T. Karampitsakos (Patras, Greece), S. Chrysikos (Athens, Greece), I. Vamvakaris (Athens, Greece), O. Papaioannou (Patras, Greece), E. Bouros (Athens, Greece), V. Tzilas (Athens, Greece), M. Katsaras (Patras, Greece), K. Dimakou (Athens, Greece), E. Manali (Athens, Greece), S. Papiris (Athens, Greece), D. Bouros (Athens, Greece), P. Bakakos (Athens, Greece), A. Tzouvelekis (Patras, Greece)
| |
Blood leukocyte levels as potential prognostic markers in IPF
A. Achaiah (Oxford, United Kingdom), A. Pereira (Oxford, United Kingdom), H. Bothwell (Oxford, United Kingdom), K. Dwivedi (Oxford, United Kingdom), A. Rathnapala (Oxford, United Kingdom), R. Barker (Oxford, United Kingdom), V. Iotchkova (Oxford, United Kingdom), R. Hoyles (Oxford, United Kingdom), L. Ho (Oxford, United Kingdom)
| |
Predicting IPF outcomes: lung function evaluation by %predicted and z-score
P. Boros (Warsaw, Poland), M. Yang (California, United States of America), K. Kirchgaessler (Basel, Switzerland), M. Martusewicz-Boros (Warsaw, Poland)
| |
PD-L1 expression in patients with idiopathic pulmonary fibrosis.
S. Kronborg-White (Aarhus N, Denmark), L. Bille Madsen (Aarhus N, Denmark), E. Bendstrup (Aarhus N, Denmark), V. Poletti (Forli, Italy)
| |
Activated lymphoid follicles, sign of an immune response, are present in early idiopathic pulmonary fibrosis (IPF) and increase with disease progression.
E. Cocconcelli (Padova (PD), Italy), G. Turato (Padova (PD), Italy), E. Bazzan (Padova (PD), Italy), A. Casara (Padova (PD), Italy), G. Fiorentù (Padova (PD), Italy), F. Calabrese (Padova (PD), Italy), F. Rea (Padova (PD), Italy), A. Sanduzzi (Naples, Italy), M. Cosio (Montreal, Canada), M. Saetta (Padova (PD), Italy), P. Spagnolo (Padova (PD), Italy), E. Balestro (Padova (PD), Italy)
| |
Lymphocyte to monocyte ratio (LMR) predicts survival in patients with Idiopathic Pulmonary Fibrosis (IPF).
N. Bernardinello (Padova, Italy), G. Grisostomi (Padova, Italy), E. Cocconcelli (Padova, Italy), G. Castelli (Padova, Italy), D. Biondini (Padova, Italy), M. Saetta (Padova, Italy), P. Spagnolo (Padova, Italy), E. Balestro (Padova, Italy)
| |
Elevated leukocyte count predicts survival in patients with idiopathic pulmonary fibrosis: analysis from the Swedish and Japanese cohorts
J. Gao (Stockholm, Sweden), D. Kalafatis (Stockholm, Sweden), H. Iwamoto (Hiroshima, Japan), H. Tanahashi (Hiroshima, Japan), K. Yamaguchi (Hiroshima, Japan), Y. Horimasu (Hiroshima, Japan), L. Carlson (Stockholm, Sweden), I. Pesonen (Stockholm, Sweden), N. Hattori (Hiroshima, Japan), M. Skold (Stockhlom, Sweden)
| |
Autoantibodies in Interstitial Lung Diseases
A. Bostanoglu (Ankara, Turkey), G. Celik (Ankara, Turkey)
| |
A systematic review and individual participant data meta-analysis of MMP-7 and outcomes in idiopathic pulmonary fibrosis
F. Khan (Nottingham, United Kingdom), I. Stewart (Nottingham, United Kingdom), G. Saini (Nottingham, United Kingdom), K. Robinson (Baltimore, Maryland, United States of America), G. Jenkins (Nottingham, United Kingdom)
| |
Feasability of home spirometry in patients with Interstitial lung disease (ILD) during the COVID-19 pandemic
C. Ruggiero (Oxford, United Kingdom), A. Achaiah (Oxford, United Kingdom), V. Nathwani (Oxford, United Kingdom), E. Fraser (Oxford, United Kingdom), R. Hoyles (Oxford, United Kingdom), P. Saunders (Oxford, United Kingdom)
| |
Cost-effectiveness of an online homemonitoring program in idiopathic pulmonary fibrosis
C. Moor (Rotterdam, Netherlands), M. Kimman (Maastricht, Netherlands), R. Mostard (Heerlen, Netherlands), J. Grutters (Nieuwegein, Netherlands), P. Bresser (Amsterdam, Netherlands), J. Aerts (Rotterdam, Netherlands), M. Wijsenbeek (Rotterdam, Netherlands)
| |
Real world patient experience of home spirometry within a UK ILD centre
C. Ruggiero (Oxford, United Kingdom), S. Hussain (Oxford, United Kingdom), A. Achaiah (Oxford, United Kingdom), E. Fraser (Oxford, United Kingdom), P. Saunders (Oxford, United Kingdom), R. Hoyles (Oxford, United Kingdom)
| |
STARLINER study; patients’ and doctors’ experiences with a digital eco-system
M. Wijsenbeek (Rotterdam, Netherlands), E. Bendstrup (Aarhus, Denmark), C. Valenzuela (Madrid, Spain), M. Henry (Cork, Ireland), M. Bengus (Basel, Switzerland), F. Gilberg (Basel, Switzerland), K. Kirchgaessler (Basel, Switzerland), C. Vancheri (Catania, Italy)
| |
Quality of life improvement after one-year integral home-care program in IPF patients that receive nintedanib
C. Ruiz Herrero (Barcelona, Spain), L. Cobo Sanchez (Barcelona, Spain), K. Portillo (Badalona, Spain), A. Boldova Loscertales (Zaragoza, Spain), A. Robles (Mataró, Spain), J. Arribas (Zaragoza, Spain), J. Figuerola (Zaragoza, Spain), R. Blavia (Sant Joan Despí, Spain), Y. Belmonte (Sant Joan Despí, Spain), A. Moreno (Barcelona, Spain), D. Castillod (Barcelona, Spain), A. Villar (Barcelona, Spain), D. Badenes (Barcelona, Spain), D. Zayas (Barcelona, Spain), G. Suarez (Hospitalet del Llobregat, Spain), L. Garcia (Mataró, Spain), E. Balcells (Barcelona, Spain), J. Sellares (Barcelona, Spain), Y. Garcia (Barbastro, Spain), S. Barril (Lleida, Spain), J. Sans (Terrassa, Spain), M. Serra (Tortosa, Spain), D. Perich (Manresa, Spain), L. Esteban (Terrassa, Spain), J. Dorca (Hospitalet del Llobregat, Spain), P. Cerda-Cortes (Barcelona, Spain), J. Palma (Hospitalet del Llobregat, Spain), E. Ruiz (Barcelona, Spain), M. Molina Molina (Hospitalet del Llobregat, Spain)
| |
EPIDIA: an App to to assist physicians in the care of patients with interstitial lung diseases
G. Tabaj (Ciudad Autónoma Buenos Aires, Argentina), B. Varela (Ciudad Autónoma Buenos Aires, Argentina), L. Sheridan (Ciudad Autónoma Buenos Aires, Argentina)
| |
Agreement in the evaluation of interstitial lung diseases between multiples observers and a mobile app in Argentina
B. Varela (Ciudad Autónoma Buenos Aires, Argentina), G. Tabaj (Ciudad Autónoma Buenos Aires, Argentina), L. Sheridan (Ciudad Autónoma Buenos Aires, Argentina)
| |